PEGINTERFERON ALFA-2B
drugOn this page
Also known as Peg-interferon alfa-2bPegifn alfa-2bPeginterferon-alfa-2bPegintronPegylated interferon alpha 2bPeg-intronSylatronViraferonpeg
Summary
Peginterferon Alfa-2B (CHEMBL1201561) is an approved protein (ATC L03AB10) targeting IFNAR1; indicated across 46 conditions including chronic hepatitis c virus infection and melanoma; with CIViC clinical evidence for 1 variant-indication association (e.g. JAK2 V617F in polycythemia vera).
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: L03AB10 (+1 more)
- Targets: 1 (IFNAR1)
- Indications: 46 conditions
- Clinical trials: 89
- Precision-oncology evidence (CIViC): 1 variant–indication association
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201561 |
| Name | PEGINTERFERON ALFA-2B |
| Type | Protein |
| Max phase | 4 |
| ATC | L03AB10, L03AB60 |
Also known as: Peg-interferon alfa-2b, Pegifn alfa-2b, Peginterferon alfa-2b, Peginterferon-alfa-2b, Pegintron, Pegylated interferon alpha 2b, Peg-intron, Sylatron, Viraferonpeg, PEGINTERFERON ALFA-2B
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| IFNAR1 | interferon α/β receptor 1 | Agonist | 0.1% | P17181 | |
| Interferon-α/β receptor | Agonist |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): IFNAR1.
Top Reactome pathways
16 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Cytokine Signaling in Immune system | 1 | IFNAR1 |
| Disease | 1 | IFNAR1 |
| Immune System | 1 | IFNAR1 |
| Infectious disease | 1 | IFNAR1 |
| Interferon alpha/beta signaling | 1 | IFNAR1 |
| Regulation of IFNA/IFNB signaling | 1 | IFNAR1 |
| Interferon Signaling | 1 | IFNAR1 |
| Potential therapeutics for SARS | 1 | IFNAR1 |
| SARS-CoV Infections | 1 | IFNAR1 |
| SARS-CoV-2 Infection | 1 | IFNAR1 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 1 | IFNAR1 |
| SARS-CoV-2-host interactions | 1 | IFNAR1 |
| Respiratory Syncytial Virus Infection Pathway | 1 | IFNAR1 |
| Viral Infection Pathways | 1 | IFNAR1 |
| Evasion by RSV of host interferon responses | 1 | IFNAR1 |
| RSV-host interactions | 1 | IFNAR1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| cell surface receptor signaling pathway via JAK-STAT | 1 |
| response to virus | 1 |
| response to lipopolysaccharide | 1 |
| cellular response to interferon-alpha | 1 |
| cellular response to interferon-beta | 1 |
| type I interferon-mediated signaling pathway | 1 |
| cellular response to virus | 1 |
| positive regulation of cellular respiration | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| positive regulation of metabolic process | 1 |
| cytokine-mediated signaling pathway | 1 |
| regulation of receptor signaling pathway via JAK-STAT | 1 |
| positive regulation of protein localization to nucleus | 1 |
Indications & clinical
Indications
46 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic hepatitis C virus infection | 4 | MONDO:0005354 | EFO:0004220 |
| melanoma | 4 | MONDO:0005105 | EFO:0000756 |
| cutaneous melanoma | 4 | MONDO:0005012 | EFO:0000389 |
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| metastatic melanoma | 4 | MONDO:0005191 | EFO:0002617 |
| chronic hepatitis B virus infection | 3 | MONDO:0005366 | EFO:0004239 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000180 |
| chronic myeloid leukemia | 3 | MONDO:0011996 | EFO:0000339 |
| plasma cell myeloma | 3 | MONDO:0009693 | EFO:0001378 |
| hepatocellular carcinoma | 3 | MONDO:0007256 | EFO:0000182 |
| essential thrombocythemia | 3 | MONDO:0005029 | EFO:0000479 |
| osteosarcoma | 3 | MONDO:0009807 | EFO:0000637 |
| AIDS | 3 | MONDO:0012268 | EFO:0000765 |
| acquired polycythemia vera | 3 | MONDO:0009891 | EFO:0002429 |
| primary myelofibrosis | 3 | MONDO:0009692 | EFO:0002430 |
| hepatitis D virus infection | 3 | MONDO:0005789 | EFO:0007304 |
| mantle cell lymphoma | 3 | MONDO:0018876 | EFO:1001469 |
| cirrhosis of liver | 3 | MONDO:0005155 | EFO:0001422 |
| hepatitis | 3 | MONDO:0002251 | HP:0012115 |
| multiple sclerosis | 3 | MONDO:0005301 | MONDO:0005301 |
| carcinoid tumor | 2 | MONDO:0005369 | EFO:0004243 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| plexiform neurofibroma | 2 | MONDO:0003304 | EFO:0000658 |
| squamous cell carcinoma | 2 | MONDO:0005096 | EFO:0000707 |
| head and neck cancer | 2 | MONDO:0005627 | EFO:0006859 |
| craniopharyngioma | 2 | MONDO:0018907 | EFO:1000209 |
| lymphoid neoplasm | 2 | MONDO:0005157 | EFO:0001642 |
| cholangiocarcinoma | 2 | MONDO:0019087 | EFO:0005221 |
| kidney cancer | 2 | MONDO:0002367 | MONDO:0002367 |
| astrocytoma (excluding glioblastoma) | 2 | MONDO:0019781 | MONDO:0016691 |
| skin carcinoma | 2 | MONDO:0002656 | EFO:0009259 |
| neurofibromatosis type 1 | 2 | MONDO:0018975 | MONDO:0018975 |
| ocular melanoma | 2 | MONDO:0006325 | EFO:1000403 |
| paraganglioma | 2 | MONDO:0000448 | EFO:1000453 |
| thrombocytopenia | 2 | MONDO:0002049 | HP:0001873 |
| renal cell carcinoma | 1 | MONDO:0005086 | EFO:0000681 |
| peritoneal neoplasm | 1 | MONDO:0006901 | MONDO:0002087 |
| fallopian tube neoplasm | 1 | MONDO:0021092 | MONDO:0002158 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 89.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 26 |
| PHASE2 | 24 |
| Not specified | 12 |
| PHASE1 | 9 |
| PHASE4 | 8 |
| PHASE2/PHASE3 | 5 |
| PHASE1/PHASE2 | 4 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05182463 | PHASE4 | RECRUITING | Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
| NCT06900166 | PHASE4 | NOT_YET_RECRUITING | Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg |
| NCT00255008 | PHASE4 | TERMINATED | Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212) |
| NCT00255034 | PHASE4 | TERMINATED | Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED) |
| NCT00854581 | PHASE4 | TERMINATED | Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma |
| NCT01532843 | PHASE4 | COMPLETED | Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB |
| NCT01683786 | PHASE4 | UNKNOWN | 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 |
| NCT02973646 | PHASE4 | UNKNOWN | Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection |
| NCT00035360 | PHASE3 | COMPLETED | Phase III PEG-Intron in HIV-infected Patients (Study P00738) |
| NCT00122629 | PHASE3 | TERMINATED | Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders |
| NCT00134030 | PHASE3 | COMPLETED | Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma |
| NCT00221702 | PHASE3 | COMPLETED | PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) |
| NCT00299936 | PHASE3 | COMPLETED | Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects |
| NCT00323804 | PHASE2/PHASE3 | COMPLETED | Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. |
| NCT00363259 | PHASE3 | COMPLETED | Pegintron Induction Therapy in HCV Non-Responders |
| NCT00687219 | PHASE3 | COMPLETED | Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) |
| NCT00689390 | PHASE2/PHASE3 | TERMINATED | Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) |
| NCT00759109 | PHASE3 | COMPLETED | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) |
| NCT00761735 | PHASE3 | COMPLETED | 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2) |
| NCT00780416 | PHASE3 | COMPLETED | Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C |
| NCT00780910 | PHASE3 | COMPLETED | Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy |
| NCT00781274 | PHASE3 | COMPLETED | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy |
| NCT01374308 | PHASE3 | UNKNOWN | NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients |
| NCT01387763 | PHASE3 | COMPLETED | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms |
| NCT01425203 | PHASE3 | COMPLETED | The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) |
| NCT01466192 | PHASE3 | COMPLETED | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients |
| NCT01468584 | PHASE3 | COMPLETED | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients |
| NCT01590225 | PHASE3 | WITHDRAWN | Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034) |
| NCT01653236 | PHASE3 | UNKNOWN | Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection |
| NCT01718301 | PHASE3 | TERMINATED | HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin |
| NCT01740089 | PHASE2/PHASE3 | COMPLETED | Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C |
| NCT01945294 | PHASE3 | COMPLETED | Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107) |
| NCT02099604 | PHASE3 | WITHDRAWN | Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C |
| NCT02103439 | PHASE3 | COMPLETED | An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients |
| NCT02204475 | PHASE3 | WITHDRAWN | Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) |
| NCT02358044 | PHASE3 | COMPLETED | Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) |
| NCT03537274 | PHASE2/PHASE3 | COMPLETED | Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) |
| NCT03552549 | PHASE2/PHASE3 | TERMINATED | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) |
| NCT04382937 | PHASE3 | COMPLETED | Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection |
| NCT00539591 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma |
Clinical evidence (CIViC)
Variant × indication × effect (1 predictive associations from 1 curated evidence items):
| Variant | Indication | Effect | Therapy | Level | CIViC |
|---|---|---|---|---|---|
| JAK2 V617F | Polycythemia Vera | Sensitivity/Response | Peginterferon Alfa-2b | CIViC B | EID19 |
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: IFNAR1
- Diseases: chronic hepatitis C virus infection, melanoma, cutaneous melanoma, neoplasm, metastatic melanoma, chronic hepatitis B virus infection, hepatitis C virus infection, HIV infectious disease, chronic myeloid leukemia, plasma cell myeloma, hepatocellular carcinoma, essential thrombocythemia, osteosarcoma, AIDS, acquired polycythemia vera, primary myelofibrosis, hepatitis D virus infection, mantle cell lymphoma, cirrhosis of liver, hepatitis, multiple sclerosis
- Biomarker genes: JAK2